Using wigner-ville distribution in ECG arrhythmia detection for telemedicine applications

39th International Conference on Telecommunications and Signal Processing, TSP 2016 -- 27 June 2016 through 29 June 2016 -- -- 125124While the world's population is growing, average life expectancy is increasing. As a result, the growing elderly population is profoundly affecting the delivery of healthcare for everyone and in particular for those with chronic diseases. The remote monitoring of chronic patients may be achieved by a telemedicine system utilizing today's information and mobile communication technologies. In this study, an ECG arrhythmia detection algorithm based on Wigner-Ville distribution is proposed. The performance of the method is tested on a large dataset obtained from the PhysioNet database. Compared to other studies, the proposed method yields better accuracy, sensitivity and specificity results. Furthermore the computation time is suitable for telemedicine applications. © 2016 IEEE.National Council for Scientific Research 114E452This research is supported by The Scientific and Technological Research Council of Turkey ( TUBTAK ) under Grant 114E45

The effect of interleukin-10 gene promoter polymorphisms on early-onset coronary artery disease [Erken başlangi{dotless}çli{dotless} koroner arter hastali{dotless}gi{dotless}nda interlökin-10 gen promotor polimorfizmlerinin etkisi]

PubMed ID: 21543297Objective: We assessed the association between interleukin-10 (IL-10) -1082G/A and -592C/A polymorphisms, and coronary heart disease (CHD). Methods: A cross-sectional, observational study included 86 patients (mean age 43.36±4.930 years) diagnosed to have CHD and 88 healthy controls (mean age 47.07±8.135 years). IL-10 -1082G/A and -592C/A polymorphisms were analyzed using restriction fragment length polymorphism (RFLP) and agarose gel electrophoresis methods in both patient and control groups. Genotype distributions of the polymorphisms between CHD patients and controls were assessed by Chi-square analysis. Results: The genotype distribution of the -1082 G/A polymorphism was not different in premature CHD patients (GG: 38.3%; GA: 51.1%; AA: 10.6%) and controls (GG: 43.1%; GC: 43.1%; CC: 13.8%) (p=0.57). The prevalence of the A allele at -1082G/A polymorphism was 36.6% in patients and 35.3% in controls. Both allele and genotype frequencies of -592C/A polymorphism did not also differ significantly between patients with CHD and controls. We did not observe relationships between polymorphism-specific haplotypes and adverse angiographic and clinical outcomes. We have observed a significant difference of IL-10 -592C/A allelic frequency (OR=2.00 95% CI=0.9434-4.2579) between the younger CHD patients (<45 years, Group 2) and matched controls. Conclusion: Our study suggests that IL-10-592C/A polymorphism may play a role in susceptibility to CHD in younger patients. © 2011 by AVES Yayi{dotless}nci{dotless}li{dotless}k Ltd

Surgical and medical management for complications in 475 consecutive pediatric cochlear implantations

PubMedID: 23290867Objective: The purpose of this study is to assess complications occurring after cochlear implantation (CI) in children and to discuss revision surgeries and medical interventions occurring during follow-up. Study design: Retrospective study of 475 consecutive pediatric cochlear implantations at a tertiary referral center. Methods: The patients (n=475) who received cochlear implants in our institution between March 2000 and March 2012 were followed up (range, 5. months-12. years). All complications were systematically reviewed, and their causes were analyzed for prevention and therapy. Results: All children received unilateral CI. Mean age at implantation was 3. years 7. months (ranged from 10. months to 18. years). Forty-three patients (9%) experienced complications. Twenty-one patients (4.4%) had major complications, consisting of device failure (10 patients), flap necrosis (4 patients), meningitis (2 patients), electrode shifting (2 patients), hematoma (2 patients) and magnet migration (1 patient). Twenty-two (4.6%) had minor complications, consisting of acute otitis media (5 patients), skin lesion due to pressure reaction in contralateral ear during surgery (4 patients), flap swelling (3 patients), minor wound infection (3 patients), transient facial paralysis (2 patients), transient vertigo (2 patients), hematoma (1 patient), facial stimulation (1 patient), subcutaneous emphysema (1 patient). Complications led to reimplantation in 13 (30.2%) and other revision surgery in 7 (16.2%) of the 43 patients. One patient with meningitis cured with medical treatment and 22 patients with minor complications cured with either medical treatment or spontaneously. Conclusions: Cochlear implantation is a safe technique in experienced hands with a relatively low complication rate. Long term follow up is mandatory to minimize and control surgical complication. © 2012

Data on prevalence of dyslipidemia and lipid values in Turkey: Systematic review and meta-analysis of epidemiological studies on cardiovascular risk factors [Türkiye'de dislipidemi sikligi ve lipit verileri: Kardiyovasküler risk faktörlerine yönelik epidemiyolojik çalişmalarin sistematik derleme ve meta-analizi]

PubMed ID: 30391985Objective: Dyslipidemias, primarily hypercholesterolemia, are independent and strong predictors of cardiovascular (CV) events. The frequency of dyslipidemia is very important in terms of determining CV prevention policies. In order to determine the up-to-date frequency of CV risk factors in Turkey, a meta-analysis of the epidemiologic studies carried out in the last 15 years was performed. This article presents the results on the dyslipidemia data including hypercholesterolemia principally. Methods: Epidemiological studies conducted during the last 15 years and having the potential to represent the general population in Turkey were searched in databases (Ovid Medline, Web of Science Core Collection, and Turkish Academic Network and Information Center [ULAKBIM]) and web pages (Ministry of Health, Turkey Statistical Institute, Turkish Society of Cardiology, Nephrology and Endocrinology Associations). A total of 7 studies including lipid data were found. Systematic review and meta-analysis of the studies with low bias score were performed. Crude values of the prevalence of hypercholeterolemia, hypertriglyceridemia and low HDL and mean lipid levels were calculated. Random effects model was used in meta-analysis. Results: The prevalence of hypercholesterolemia defined as a LDL-cholesterol >130 and/or ?130 mg/dL, was 29.1% (95% CI 23.6-35.0) in the general population, 30.2% in females (%95 CI 24.7-36.1), and 27.8% in males (95% CI 22.3-33.6). The prevalence of low HDL-cholesterol (?50 mg/dL for females and ?40 mg/dL for males) was calculated as 46.1% (95% CI 42.4-49.9) in the whole group, 50.7% (95% CI 47.7-53.6) in females and 41.1% (95% CI 36.1-46.3) in males. The prevalence of hypertriglyceridemia (>150 mg/dL) was 36.5% (95% CI 30.6-42.5) in general, 32.0% (95% GA 26.6-37.8) in females and 41.3% (95% CI 34.9-47.8) in males. Conclusion: Dyslipidemia constitutes a major public health problem in Turkey. In the adult population, almost 3 of 10 have hypercholesterolemia, one of 2 has a low HDL-cholesterol, and 1 of 3 has high triglycerides levels. © 2016 Archives of the Turkish Society of Cardiology

EUROASPIRE III: A comparison between Turkey and Europe [EUROASPIRE III: Türkiye ile Avrupa'nin karşilaştirilmasi]

PubMed ID: 20675993Objectives: The EUROASPIRE III survey was conducted in 2006-2007 in 22 countries in Europe (76 centers) to describe risk factors, lifestyle and therapeutic management of patients with coronary heart disease (CHD), compliance with current guidelines, and to document changes over time. This study aimed to assess the results of the EUROASPIRE III survey in terms of differences between Turkey and other European countries. Study design: The results of the EUROASPIRE III survey were compared with those of 17 centers from Turkey. Consecutive patients with a diagnosis of CHD (669 medical records, %23.8 women) were identified retrospectively, of which 338 patients (50.5%) were followed-up, interviewed, and examined at least six months after the index event (acute coronary syndrome or interventional procedure). Results: Compared to the EUROASPIRE III data, recordings from Turkey's centers at discharge on classical risk factors did not exhibit remarkable differences; however, data on weight, height, waist circumference, lipid profile, glucose, and HbA1c measurements were more incomplete. In comparison to Europe population, the most important differences were observed in the higher rates of the following: young patients with myocardial infarction (<50 years, 20% vs. 12.7%), persistence in smoking (23.1% vs. 17.2%), immobility, low HDL-cholesterol (50.2% vs. 36.7%), insufficient follow-up by physicians after the index event (12% vs. 2.2%-except Turkey), and insufficient patient education. Conclusion: The data from the Turkey arm of the survey show that efforts for cardiovascular disease prevention fall short of the targets, similar to Europe

Reducing the clinical and public health Burden of Familial hypercholesterolemia

Importance Familial hypercholesterolemia (FH) is an underdiagnosed and undertreated genetic disorder that leads to premature morbidity and mortality due to atherosclerotic cardiovascular disease. Familial hypercholesterolemia affects 1 in 200 to 250 people around the world of every race and ethnicity. The lack of general awareness of FH among the public and medical community has resulted in only 10% of the FH population being diagnosed and adequately treated. The World Health Organization recognized FH as a public health priority in 1998 during a consultation meeting in Geneva, Switzerland. The World Health Organization report highlighted 11 recommendations to address FH worldwide, from diagnosis and treatment to family screening and education. Research since the 1998 report has increased understanding and awareness of FH, particularly in specialty areas, such as cardiology and lipidology. However, in the past 20 years, there has been little progress in implementing the 11 recommendations to prevent premature atherosclerotic cardiovascular disease in an entire generation of families with FH. Observations In 2018, the Familial Hypercholesterolemia Foundation and the World Heart Federation convened the international FH community to update the 11 recommendations. Two meetings were held: one at the 2018 FH Foundation Global Summit and the other during the 2018 World Congress of Cardiology and Cardiovascular Health. Each meeting served as a platform for the FH community to examine the original recommendations, assess the gaps, and provide commentary on the revised recommendations. The Global Call to Action on Familial Hypercholesterolemia thus represents individuals with FH, advocacy leaders, scientific experts, policy makers, and the original authors of the 1998 World Health Organization report. Attendees from 40 countries brought perspectives on FH from low-, middle-, and high-income regions. Tables listing country-specific government support for FH care, existing country-specific and international FH scientific statements and guidelines, country-specific and international FH registries, and known FH advocacy organizations around the world were created. Conclusions and Relevance By adopting the 9 updated public policy recommendations created for this document, covering awareness; advocacy; screening, testing, and diagnosis; treatment; family-based care; registries; research; and cost and value, individual countries have the opportunity to prevent atherosclerotic heart disease in their citizens carrying a gene associated with FH and, likely, all those with severe hypercholesterolemia as well

Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia: A Global Call to Action.

Importance: Familial hypercholesterolemia (FH) is an underdiagnosed and undertreated genetic disorder that leads to premature morbidity and mortality due to atherosclerotic cardiovascular disease. Familial hypercholesterolemia affects 1 in 200 to 250 people around the world of every race and ethnicity. The lack of general awareness of FH among the public and medical community has resulted in only 10% of the FH population being diagnosed and adequately treated. The World Health Organization recognized FH as a public health priority in 1998 during a consultation meeting in Geneva, Switzerland. The World Health Organization report highlighted 11 recommendations to address FH worldwide, from diagnosis and treatment to family screening and education. Research since the 1998 report has increased understanding and awareness of FH, particularly in specialty areas, such as cardiology and lipidology. However, in the past 20 years, there has been little progress in implementing the 11 recommendations to prevent premature atherosclerotic cardiovascular disease in an entire generation of families with FH. Observations: In 2018, the Familial Hypercholesterolemia Foundation and the World Heart Federation convened the international FH community to update the 11 recommendations. Two meetings were held: one at the 2018 FH Foundation Global Summit and the other during the 2018 World Congress of Cardiology and Cardiovascular Health. Each meeting served as a platform for the FH community to examine the original recommendations, assess the gaps, and provide commentary on the revised recommendations. The Global Call to Action on Familial Hypercholesterolemia thus represents individuals with FH, advocacy leaders, scientific experts, policy makers, and the original authors of the 1998 World Health Organization report. Attendees from 40 countries brought perspectives on FH from low-, middle-, and high-income regions. Tables listing country-specific government support for FH care, existing country-specific and international FH scientific statements and guidelines, country-specific and international FH registries, and known FH advocacy organizations around the world were created. Conclusions and Relevance: By adopting the 9 updated public policy recommendations created for this document, covering awareness; advocacy; screening, testing, and diagnosis; treatment; family-based care; registries; research; and cost and value, individual countries have the opportunity to prevent atherosclerotic heart disease in their citizens carrying a gene associated with FH and, likely, all those with severe hypercholesterolemia as well